| Press Release

UgenTec is now part of Velsera

Boston, San Francisco, Stockholm – January 12, 2023

Announcing SENTiNAT®200, a brand new sample-to-result platform-8

Sentinel Diagnostics today announced its new end-to-end platform for molecular diagnostics, dubbed SENTiNAT®200. The platform will support the full ra...

Announcing SENTiNAT®200, a brand new sample-to-result platform

Sentinel Diagnostics today announced its new end-to-end platform for molecular diagnostics, dubbed SENTiNAT®200. The platform will support the full ra...

Announcing SENTiNAT®200, a brand new sample-to-result platform-5

Sentinel Diagnostics today announced its new end-to-end platform for molecular diagnostics, dubbed SENTiNAT®200. The platform will support the full ra...

Announcing SENTiNAT®200, a brand new sample-to-result platform

Sentinel Diagnostics today announced its new end-to-end platform for molecular diagnostics, dubbed SENTiNAT®200. The platform will support the full ra...

Announcing SENTiNAT®200, a brand new sample-to-result platform

Sentinel Diagnostics today announced its new end-to-end platform for molecular diagnostics, dubbed SENTiNAT®200. The platform will support the full ra...

For the latest version of the instructions for use, click this link. IFU in paper format can be requested at support@ugentec.com.

Kempische Steenweg 303/105, 3500 Hasselt Belgium (map)
1 Mifflin Place, Suite 400 Cambridge, MA 02138, USA (map)

Legal documents

Contact: info@ugentec.com | +32 78 48 44 79 | VAT number: BE05 5197 6421